1. SAT0244 Impact of 12 weeks of upadacitinib treatment on individual and composite disease measures in patients with rheumatoid arthritis and inadequate response to conventional synthetic or biologic dmards. (12th June 2018) Authors: van Vollenhoven, R.; Dore, R.; Chen, K.; Camp, H. S.; Enejosa, J.; Shaw, T.; Suboticki, J. L.; Hall, S. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗